US · Healthcare · Diagnostics & Research
EPS came in at 1.31 against a street estimate of 1.23 — a beat of 6.5%.
Analysts rate Illumina Inc a buy (11 buy, 6 hold, 3 sell out of 20) with an average price target of $193.05.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.57% |
| Capital World Investors | 10.28% |
| Vanguard Portfolio Management, LLC | 4.51% |
| Vanguard Capital Management, LLC | 4.36% |
| State Street Corp | 4.25% |
| WCM Investment Management | 3.91% |
| AQR Capital Management LLC | 2.63% |
| Corvex Management LP | 2.53% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-31 |
| Results announced · Q3 2026 | 2026-07-30 |
| Board / officer change · Q2 2026 | 2026-06-23 |
| Shareholder vote results · Q2 2026 | 2026-05-26 |
| Quarterly report · Q1 2026 | 2026-05-04 |
| Results announced · Q2 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-04-09 |
| Annual report FY2025 | 2026-02-12 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1028 : 1000 effective Jun 25, 2024 | 2024-06-25 |
| Announcement | Date |
|---|---|
| Board authorizes new $1.5 billion share repurchase program Illumina announced Q1 2026 financial results on April 30, 2026. The document itself contains minimal details—the actual earnings numbers and performance metrics are in the attached press rel | 2026-04-30 |
| Completion of transaction acquisition announced Illumina, Inc. announced on January 30, 2026, that it has completed its acquisition of Standard BioTools Inc., a deal originally announced in June 2025. The 8-K filing confirms the transacti | 2026-01-30 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Illumina Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.